MAPK3 and familial pancreatic carcinoma: These results are consistent with our previous study [8], suggesting that ERK1/2 activity may protect pancreatic cancer cells from gemcitabine-induced apoptosis, and ERK1/2 silencing sensitized BXPC-3 cells to Gem-induced apoptosis.